ArticlePloS one2025
Pilot-scale depuration demonstrates the suitability of non-pathogenic Vibrio parahaemolyticus as a surrogate for commercial-scale validation studies.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shellfish producers have proposed using depuration systems to reduce Vibrio parahaemolyticus levels by supporting the oysters' natural purging ability. For commercial viability, depuration efficacy must be validated in relevant species and at scale using appropriate conditions, including time and temperature. This study aims to I) compare depuration efficacy across oyster species, II) assess non-pathogenic V. parahaemolyticus as a surrogate, and III) optimize pilot-scale depuration to identify process variables likely to achieve >3.0-log reduction of V. parahaemolyticus at commercial-scale. Three oyster species (Crassostrea gigas, Crassostrea sikamea, Crassostrea virginica) were exposed to artificial seawater (35 ppt) containing five non-pathogenic or five pathogenic V. parahaemolyticus strains. Inoculated oysters were placed in a pilot-scale recirculating depuration system at 5, 11, or 13 °C for 7 days. Three replicate depuration trials were conducted, sampling five oysters per species and the two different bacterial inoculations every 24 hours. V. parahaemolyticus in oyster tissue was enumerated using serial dilutions and spread plating techniques on Thiosulfate-Citrate-Bile Salts-Sucrose agar. In C. gigas and C. sikamea, inoculation achieved at least a 5 log CFU/g V. parahaemolyticus, but C. virginica did not consistently reach target density within 24 hours. Accumulation of non-pathogenic and pathogenic strains was similar across species. Depuration at 11°C achieved a > 3 log CFU/mL reduction of the pathogenic strain combination in C. gigas and C. sikamea tissues within five days, while C. virginica averaged 2.8 log CFU/mL. V. parahaemolyticus clearance rate was rapid during the first 24-48 hours of depuration. The non-pathogenic V. parahaemolyticus strain combination was reduced at a comparable or slower rate than the pathogenic combination, supporting its suitability as a surrogate for commercial validations. These findings support depuration as an effective V. parahaemolyticus mitigation strategy in live oysters; though optimization of parameters, including temperature and duration, is needed to meet reduction targets in all species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.